Late last year, we discussed the dismissal of three purported California no-injury class actions alleging that certain over the counter (“OTC”) acne medicines were contaminated with carcinogenic benzene.  That post also commented:

By the way, guess who says they found the benzene in the products?  It was that good, old “independent” lab, Valisure −  which proceeded to file a citizen’s petition with the FDA seeking action against [these] products.  Sound familiar?

Last month, the FDA responded to the petition.  The agency was not impressed.  Its own testing – contrary to Valisure’s overblown claims in its petition (“detected high levels of benzene . . . in many specific batches”) found practically nothing to be concerned about.  It tested “95 acne products containing benzoyl peroxide for possible benzene contamination,” and “more than 90% of tested products had undetectable or extremely low levels of benzene.”  FDA, Statement ¶1 (March 11, 2025). THe FDA initiated a “limited number of voluntary recalls” due to “findings show[ing] a small number of products with elevated levels of benzene contamination.” Id.  Only six of 95 products were recalled, and even then, only specified lot numbers.  FDA Statement ¶7.

Continue Reading It’s About Time – FDA Calls Foul on Valisure

This post is not from the Reed Smith or Dechert sides of the blog.

We previously posted about the Delaware Supreme Court’s ruling that proper application of Delaware Rule 702 required the exclusion of plaintiffs’ general causation experts in the Zantac litigation. Since then, we’ve been waiting for the other shoe to drop.  Last week, it dropped with a resounding boom. Today’s decision applied the Delaware Supreme Court’s ruling and dismissed over 80,000 cases. In re Zantac (Ranitidine) Litig., No. N22C-090101, 2026 WL 1009008 (Del. Super. Apr. 14, 2026).

The decision focuses on the question of which plaintiffs are bound by the exclusion of the plaintiffs’ general causation experts. The court denied plaintiffs leave to supplement their expert reports on December 1, 2025, and the defense argued that all plaintiffs with cases filed before December 1, 2025, are bound by the ruling. Recognizing that the litigation was about to be eviscerated, plaintiffs made a number of desperate arguments.

Continue Reading No Mulligans in Delaware – Exclusion of Plaintiffs’ General Causation Experts Results in Dismissal of 80,000 Zantac Cases

A federal judge in California filed an important OTC preemption decision earlier this month, and it’s important because it applied federal preemption to shut down (for now) one of the many recent benzene-related consumer class actions.  The case is Daugherty v. Padagis US LLC, No. 24-cv-02066, 2025 WL 2243622 (N.D. Cal. Aug. 6, 2025)

Today we address two more cooked-up—literally—Valisure cases, Bodunde v. Walgreens Boots Alliance, Inc., No. 1:24-CV-00985-JLT-SAB, 2025 WL 1411306 (E.D. Cal. May 15, 2025), and Navarro v. Walgreens Boots Alliance, Inc., No. 1:24-CV-00290-JLT-SAB, 2025 WL 1411406 (E.D. Cal. May 15, 2025).

These two cases involve legally identical magistrate recommendations that Defendant’s motions to dismiss

For several years now, the Valsartan MDL has been something of a poster child for the problems with modern serial product liability litigation.  It started with questionable data coming out of a questionable lab, leading to publicity and regulatory actions that outpaced reliable evidence of increased risk from an alleged carcinogenic contamination.  It snowballed